Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Oral TY-302 Capsules Combined With Abiratone Acetate Tablets in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) That Has Failed Novel Endocrine Therapy

NCT07104617 is registered in ClinicalTrials.gov with TYK Medicines, Inc as lead sponsor.

NCT NCT07104617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07104617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Oral TY-302 Capsules Combined With Abiratone Acetate Tablets in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) That Has Failed Novel Endocrine Therapy
Lead sponsor
TYK Medicines, Inc
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 31, 2025
Completion date
November 30, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer (mcrpc)